^
Association details:
Biomarker:No biomarker
Cancer:Malignant Pleural Mesothelioma
Drug:Cyramza (ramucirumab) (VEGFR-2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Published date:
12/15/2022
Excerpt:
Mesothelioma: Pleural...Subsequent Systemic Therapy...Other recommended...Gemcitabine + ramucirumab added as a treatment option
Secondary therapy:
gemcitabine
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Excerpt:
Recommendations...Systemic therapy for second line and beyond…Single-agent gemcitabine or vinorelbine [II, B] have limited second-line activity, as suggested by ORRs or OS, with encouraging activity for gemcitabine–ramucirumab combination [III, C].
Secondary therapy:
gemcitabine
DOI:
https://doi.org/10.1016/j.annonc.2021.11.005